Hualan Biological Engineering, Inc. is a high-risk biopharmaceutical company based in China. Specializing in the research, development, and commercialization of plasma products, viral vaccines, bacterial vaccines, and recombinant proteins. The company offers a variety of products such as Human albumin, Recombinant hepatitis B vaccine, and Monoclonal Antibody for various diseases. With a ESG score of 30.4, they are committed to sustainability and governance practices.